1. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.

2. Federal Trade Commission. Generic Drug Entry Prior to Patent Expiration: an FTC study. 2002, July. Available online at: www.ftc.gov/os/2002/07/genericdrugstudy.pdf (accessed 1 November 2007).

3. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.

4. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.

5. Adams S. Roche versus Adams. London: J. Cape; 1984.

6. Clinard M.B., Yeager P.C. Corporate Crime. New Brunswick: Transaction Publishers; 2006.

7. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.

8. Nelson R. Debate over ritonavir price increase gains momentum. Lancet. 2004; 363: 1369.

9. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.

10. Hemmingsen M.A. [Antidepressant medicine increases by 1200 percent in three months]. Dagens Medicin. 2010 Sept 17.

11. Andersen L. [Drug prices will be trenched]. Jyllandsposten. 2007 March 30.

12. Dilling S. [Price for cholesterol lowering drug explodes]. Politiken. 2007 March 28.

13. Svansø V.L. [Lundbeck purchase costs a court case]. Berlingske. 2009 Feb 21.

14. Drug company granted monopoly – price of drug increases 15000%. Pioneer Press. 2011 March 14.

15. Messori A., Cicchetti A., Patregani L. Relating price determination to disease prevalence. BMJ. 2010; 341: 417–18.

16. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest. 2006; 116: 2837–42.

17. PBS. The Other Drug War. Interview with Marcia Angell. 2002 Nov 26. Available online at: www.pbs.org/wgbh/pages/frontline/shows/other/interviews/angell.html (accessed 4 April 2005).

18. Steenberger A., Larsen K., Bundgaard B. [The minister of health wishes to discuss prioritization with the regions]. Ugeskr Læger. 2011; 173: 472.

19. Svansø V.L., Hyltoft V. [The regions at war with the drug industry]. Berlingske. 2011 Feb 3.

20. Quotations. Ugeskr Læger. 2010; 172: 1568.

21. Svansø V.L., Hyltoft V. [Drug industry under pressure]. Berlingske. 2011 Feb 3.

22. Cumming J., Mays N., Daubé J. How New Zealand has contained expenditure on drugs. BMJ. 2010; 340: 1224–7.

23. Mintzberg H. Patent nonsense: evidence tells of an industry out of social control. CMAJ. 2006; 175: 374.

24. Stevens A.J., Jensen J.J., Wyller K., et al. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med. 2011; 364: 535–41.

25. Light D.W., Lexchin J.R. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012; 344: e4348.

26. The Association of the British Pharmaceutical Industry. Guidance on Collaboration between Healthcare Professionals and the Pharmaceutical Industry. 2012 March 29. Available online at: www.abpi.org.uk/our-work/library/guidelines/Pages/collaboration-guidance.aspx (accessed 27 December 2012).

27. Braillon A., Bewley S., Herxheimer A., et al. Marketing versus evidence-based medicine. Lancet. 2012; 380: 340.

28. Goldacre B. Bad Pharma. London: Fourth Estate; 2012.

29. Beran D., Capewell S., de Courten M., et al. The International Diabetes Federation: losing its credibility by partnering with Nestlé? Lancet. 2012; 380: 805.

30. Danish Association of the Pharmaceutical Industry. [Revised collaborative agreement between the Medical Association and the Danish Association of the Pharmaceutical Industry about clinical trials and non-intervention studies]. 2010 June 1.

31. Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.

32. Huskisson E.C., Woolf D.L., Balme H.W., et al. Four new anti-inflammatory drugs: responses and variations. Br Med J. 1976; 1: 1048–9.